Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hutchmed China Ltd ADR (NQ: HCM )

21.01 +1.06 (+5.31%)
Official Closing Price Updated: 4:15 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Hutchmed China Ltd ADR

< Previous 1 2 3 Next >
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
From HUTCHMED (China) Limited
Via GlobeNewswire
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts
Virtual Investor Conference on November 8th and 9th, 2023 
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial — 
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Reports 2023 Interim Results and Provides Business Updates
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces Changes to Board of Directors and Technical Committee
Ms Ling Yang to replace Mr Lefei Sun as Non-executive Director; Professor Solange Peters appointed as Special Advisor to the Technical Committee 
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED to Announce 2023 Half-Year Financial Results
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
From HUTCHMED (China) Limited
Via GlobeNewswire
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings
From HUTCHMED (China) Limited
Via GlobeNewswire
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces Board of Directors and Board Committee Membership
From HUTCHMED (China) Limited
Via GlobeNewswire
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees
From HUTCHMED (China) Limited
Via GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023
From HUTCHMED (China) Limited
Via GlobeNewswire
Intended Retirement of Independent Non-executive Director
From HUTCHMED (China) Limited
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.